Evicenter
MarkdownMedical informationP&T meetings
Lorundrostat (MLS-101)

Hypertension, in combination with other antihypertensive drugs

Also known as MT-4129
Launch
Not announced
Last updated
198 sources

Clinical evidence

MT-4129-E01

57 evidence topics · 4 sources

Objective
Location and study date
Registered site, sponsor, and dates
FieldQuoted record
Location“Pharmaceutical Research Associates (PRA) Health Sciences”
Sponsor“Tanabe Pharma Corporation”
Other study ID number“MT-4129-E01”
Study start“2016-11”
Primary completion (actual)“2017-05”
Study completion (actual)“2017-05”
Study design
Registered design details
FieldQuoted record
Phase“Phase 1”
Allocation“Randomized”
Interventional model“Parallel Assignment”
Masking“Double”
Primary purpose“Other”
Eligibility criteria
Treatment
Study outcomes
Rationale for using adverse events as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographics by dose group and part
Dose groupAge, years, mean (SD)Sex, n (%)Weight, kg, mean (SD)BMI (kg/m2), mean (SD)
Part 1, placebo (n = 16)“31.2 (12.9)”View highlighted excerpt for this quoteMale: “16 (100)”View highlighted excerpt for this quote“81.0 (7.8)”View highlighted excerpt for this quote“24.8 (2.1)”View highlighted excerpt for this quote
Part 1, 5 mg (n = 6)“29.0 (12.3)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“71.5 (5.3)”View highlighted excerpt for this quote“22.5 (1.8)”View highlighted excerpt for this quote
Part 1, 10 mg (n = 6)“31.7 (13.1)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“78.3 (12.4)”View highlighted excerpt for this quote“23.9 (3.7)”View highlighted excerpt for this quote
Part 1, 20 mg (n = 6)“27.5 (12.7)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“76.2 (7.6)”View highlighted excerpt for this quote“23.8 (2.8)”View highlighted excerpt for this quote
Part 1, 50 mg (n = 6)“28.2 (13.8)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“77.3 (7.2)”View highlighted excerpt for this quote“22.8 (2.2)”View highlighted excerpt for this quote
Part 1, 100 mg (n = 6)“27.8 (11.9)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“79.2 (8.7)”View highlighted excerpt for this quote“23.4 (1.9)”View highlighted excerpt for this quote
Part 1, 200 mg (n = 6)“28.3 (11.8)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“81.4 (12.3)”View highlighted excerpt for this quote“23.4 (2.3)”View highlighted excerpt for this quote
Part 1, 400 mg (n = 6)“28.5 (11.9)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“84.2 (6.8)”View highlighted excerpt for this quote“24.2 (2.8)”View highlighted excerpt for this quote
Part 1, 800 mg (n = 6)“33.2 (15.8)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“85.1 (9.9)”View highlighted excerpt for this quote“25.1 (2.9)”View highlighted excerpt for this quote
Part 2, placebo (n = 9)“29.3 (11.9)”View highlighted excerpt for this quoteMale: “9 (100)”View highlighted excerpt for this quote“78.5 (10.2)”View highlighted excerpt for this quote“23.6 (2.9)”View highlighted excerpt for this quote
Part 2, 40 mg (n = 9)“29.2 (10.4)”View highlighted excerpt for this quoteMale: “9 (100)”View highlighted excerpt for this quote“76.7 (8.6)”View highlighted excerpt for this quote“23.0 (2.3)”View highlighted excerpt for this quote
Part 2, 120 mg (n = 9)“26.3 (5.6)”View highlighted excerpt for this quoteMale: “9 (100)”View highlighted excerpt for this quote“77.8 (12.2)”View highlighted excerpt for this quote“22.8 (2.6)”View highlighted excerpt for this quote
Part 2, 360 mg (n = 9)“30.8 (11.6)”View highlighted excerpt for this quoteMale: “9 (100)”View highlighted excerpt for this quote“76.4 (11.7)”View highlighted excerpt for this quote“23.1 (4.1)”View highlighted excerpt for this quote
Part 3, placebo (n = 2)“23.0 (4.2)”View highlighted excerpt for this quoteFemale: “2 (100)”View highlighted excerpt for this quote“59.9 (8.9)”View highlighted excerpt for this quote“22.3 (3.3)”View highlighted excerpt for this quote
Part 3, 100 mg (n = 6)“25.5 (5.8)”View highlighted excerpt for this quoteFemale: “6 (100)”View highlighted excerpt for this quote“60.8 (4.7)”View highlighted excerpt for this quote“22.2 (1.7)”View highlighted excerpt for this quote
Part 4, placebo (n = 2)“72.5 (3.5)”View highlighted excerpt for this quoteMale: “2 (100)”View highlighted excerpt for this quote“77.2 (10.6)”View highlighted excerpt for this quote“27.9 (1.0)”View highlighted excerpt for this quote
Part 4, 100 mg (n = 6)“72.2 (4.1)”View highlighted excerpt for this quoteMale: “6 (100)”View highlighted excerpt for this quote“77.9 (6.3)”View highlighted excerpt for this quote“25.1 (1.9)”View highlighted excerpt for this quote
Efficacy results
Plasma pharmacokinetic parameters by dose
Dose groupAUC, ng × h/mL, mean (SD)Cmax, ng/mL, mean (SD)t1/2, h, mean (SD)Tmax, h, median (minimum–maximum)
Single dose, 5 mg (AUC0–∞)“232 (25)”View highlighted excerpt for this quote“36.7 (6.7)”View highlighted excerpt for this quote“8.3 (0.7)”View highlighted excerpt for this quote“1.5 (1.0–3.0)”View highlighted excerpt for this quote
Single dose, 10 mg (AUC0–∞)“452 (46)”View highlighted excerpt for this quote“76.3 (20.4)”View highlighted excerpt for this quote“7.9 (0.9)”View highlighted excerpt for this quote“1.3 (1.0–1.5)”View highlighted excerpt for this quote
Single dose, 20 mg (AUC0–∞)“770 (183)”View highlighted excerpt for this quote“140.6 (76.1)”View highlighted excerpt for this quote“10.0 (1.9)”View highlighted excerpt for this quote“1.5 (1.0–3.0)”View highlighted excerpt for this quote
Single dose, 50 mg (AUC0–∞)“2157 (259)”View highlighted excerpt for this quote“572.8 (205.7)”View highlighted excerpt for this quote“9.1 (1.9)”View highlighted excerpt for this quote“1.0 (0.5–3.0)”View highlighted excerpt for this quote
Single dose, 100 mg (AUC0–∞)“5376 (495)”View highlighted excerpt for this quote“1211.0 (248.3)”View highlighted excerpt for this quote“10.0 (0.9)”View highlighted excerpt for this quote“1.5 (0.5–3.0)”View highlighted excerpt for this quote
Single dose, 200 mg (AUC0–∞)“10,660 (3483)”View highlighted excerpt for this quote“2847.5 (1015.2)”View highlighted excerpt for this quote“9.9 (3.6)”View highlighted excerpt for this quote“1.3 (1.0–3.0)”View highlighted excerpt for this quote
Single dose, 400 mg (AUC0–∞)“17,275 (2906)”View highlighted excerpt for this quote“4454.8 (862.4)”View highlighted excerpt for this quote“9.7 (2.3)”View highlighted excerpt for this quote“1.3 (0.5–3.0)”View highlighted excerpt for this quote
Single dose, 800 mg (AUC0–∞)“29,385 (3623)”View highlighted excerpt for this quote“7708.5 (1617.1)”View highlighted excerpt for this quote“10.5 (2.1)”View highlighted excerpt for this quote“1.5 (0.5–4.0)”View highlighted excerpt for this quote
Multiple dose, 40 mg, Day 7 (AUC0–24)“1795.0 (312.0)”View highlighted excerpt for this quote“365.1 (46.5)”View highlighted excerpt for this quote“9.1 (1.8)”View highlighted excerpt for this quote“2.0 (1.0–3.0)”View highlighted excerpt for this quote
Multiple dose, 120 mg, Day 7 (AUC0–24)“5816.0 (1315.0)”View highlighted excerpt for this quote“1038.7 (342.8)”View highlighted excerpt for this quote“11.9 (2.5)”View highlighted excerpt for this quote“1.5 (0.5–5.0)”View highlighted excerpt for this quote
Multiple dose, 360 mg, Day 7 (AUC0–24)“21825.0 (3955.0)”View highlighted excerpt for this quote“3812.1 (1282.3)”View highlighted excerpt for this quote“9.2 (2.5)”View highlighted excerpt for this quote“2.5 (1.0–4.0)”View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes

Not applicable.

Safety results
Treatment-related adverse events after single doses
Preferred term, n (%)Placebo (n = 16)5 mg (n = 6)10 mg (n = 6)20 mg (n = 6)50 mg (n = 6)100 mg (n = 6)200 mg (n = 6)400 mg (n = 6)800 mg (n = 6)
Headache“2 (12.5)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Somnolence“1 (6.3)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Dizziness“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Diarrhea“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (16.7)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Nausea“1 (6.3)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Asthenia“1 (6.3)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Treatment-related adverse events after multiple doses
Preferred term, n (%)Part 2, placebo (n = 9)Part 2, 40 mg (n = 9)Part 2, 120 mg (n = 9)Part 2, 360 mg (n = 9)
Headache“2 (22.2)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Dizziness postural“0 (0.0)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote
Somnolence“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote
Dizziness“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Dysgeusia“0 (0.0)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Sinus tachycardia“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote
Dyspnea“1 (11.1)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Nausea“0 (0.0)”View highlighted excerpt for this quote“1 (11.1)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote“0 (0.0)”View highlighted excerpt for this quote
Study limitations
Summary

MT-4129-E01 randomized 116 healthy white participants at one center in the Netherlands. Parts 1 and 2 enrolled men aged 18 to 55 years only, and the effects of sex and of age were each assessed in one cohort of 8 participants, 6 of whom received a single 100 mg dose. Multiple dosing lasted 7 days, so the study gives no information on longer treatment or on people with hypertension. Lorundrostat was given as a capsule whose exposure the authors state is about 50% of that of the tablet used in the phase 2 study, the comparison of fed and fasted pharmacokinetics was exploratory with no formal statistical comparison, and the formal tablet food effect study is described as “data on file”. The ClinicalTrials.gov record lists enrollment as estimated. The concentration-QTc analysis is reported in a congress poster by authors from Mineralys Therapeutics and Clario. The publication states that the studies it reports were funded by Mineralys Therapeutics, while the registry record names Tanabe Pharma Corporation as sponsor, and the authors include employees of Mitsubishi Tanabe Pharma Corporation, Mineralys Therapeutics, and ICON, the contract research organization that conducted the study.